RxDoctor Payments Data

Zaid Said, MD

Cardiovascular Disease · Braselton, GANPI 1215251897

Payments from drug & device makers

$3,398in general payments, 2019–2025

Across 162 payments — averaging $20.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$497
  • Heartflow, Inc.$468
  • Amgen$450
  • Boston Scientific$346
  • Merck$278
  • Johnson & Johnson$250
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,37899%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,398 in reported general payments places this provider in the 55th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$214,375
Medicare patients
2,129
Services billed
5,039

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban353$422,850
XareltoRivaroxaban135$151,351
EntrestoSacubitril/Valsartan129$127,291
Repatha SureclickEvolocumab109$106,966
FarxigaDapagliflozin Propanediol99$102,315
JardianceEmpagliflozin62$73,470
VascepaIcosapent Ethyl31$23,987
Repatha PushtronexEvolocumab31$23,220
Praluent PenAlirocumab26$22,610
BrilintaTicagrelor20$8,722
Metoprolol Succinate401$5,435
Rosuvastatin Calcium453$5,434
Atorvastatin Calcium593$5,001
Ranolazine ErRanolazine31$4,740
Clonidine20$4,344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$497$422,850353 claims
Johnson & JohnsonXarelto$250$151,351135 claims
NovartisEntresto$117$127,291129 claims
AstraZenecaFarxiga, Brilinta$168$111,037119 claims
Boehringer IngelheimJardiance$20$73,47062 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →